Kimberly A. Reed
Known title: DirectorCIK: 0001873931
Associated companies
this person other insiders at TAK
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Momentus Secures NASA Contract for FALCON-Lidar Mission. Momentus has been awarded a NASA task order to support the initial phase of the FALCON-Lidar mission, which will study Earth’s atmosphere. This contract adds a new source of revenue for the company and highlights its role in space-based scientific research. The news provides a fundamental update for the stock, which is currently trading well below its 52-week high.
Transaction History
| TAK | ▲ Buy | Grant | 3,800 | $0 | 7/1/2026 | View on chart |
| MNTS | ▲ Buy | Option Exercise | 913 | $0 | 5/18/2026 | View on chart |
| MNTS | ▲ Buy | Grant | 16,294 | $0 | 6/30/2025 | View on chart |
| MNTS | ▲ Buy | Option Exercise | 222 | $0 | 11/1/2024 | View on chart |
| MNTS | ▲ Buy | Option Exercise | 2,400 | $0 | 11/1/2024 | View on chart |
| MNTS | ▲ Buy | Option Exercise | 11,111 | $0 | 8/12/2023 | View on chart |
| MNTS | ▲ Buy | Option Exercise | 86,206 | $0 | 5/30/2023 | View on chart |
| MNTS | ▲ Buy | Option Exercise | 11,111 | $0 | 8/12/2022 | View on chart |
| MNTS | ▲ Buy | Option Exercise | 17,857 | $0 | 5/30/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Takeda Launches Narcolepsy Drug in Asia, Presents PID Study Data
Takeda has launched its new narcolepsy treatment, ORZEYFUL, in Japan and China, marking the first availability of this orexin agonist for patients with narcolepsy type 1. The company also presented Phase 2/3 clinical data for its investigational drug TAK-881 for primary immunodeficiency disease at a recent medical conference. These pipeline advancements represent key milestones in Takeda's therapeutic portfolio expansion.
Takeda Launches Narcolepsy Drug in Asia, Presents PID Study Data. Takeda has launched its new narcolepsy treatment, ORZEYFUL, in Japan and China, marking the first availability of this orexin agonist for patients with narcolepsy type 1. The company also presented Phase 2/3 clinical data for its investigational drug TAK-881 for primary immunodeficiency disease at a recent medical conference. These pipeline advancements represent key milestones in Takeda's therapeutic portfolio expansion.